Pharma major Lupin on Friday said it has launched generic immunosuppressant Mycophenolate Mofetil capsules in the US.
The company has launched Mycophenolate Mofetil capsules USP in the strength of 250 mg. Its alliance partner Concord Biotech had earlier received an approval from the United States Food and Drug Administration (USFDA) for the product, Lupin said in a statement.
The product is a generic version of Roche's CellCept capsules, it added.
As per IQVIA MAT August 2019 data, Mycophenolate Mofetil capsules USP, 250 mg, had annual sales of around USD 53 million in the US, Lupin said.
The capsules are an "antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, and should be used in combination with other immunosuppressants", it added.
Shares of Lupin closed at Rs 686.60 per scrip on BSE, down 2.06 per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app